Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure

• Status: Unknown status
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of Cardiac Sympathetic Blockade on Mortality, re-hospitalization rate, symptoms, quality of life, exercise tolerance, cardiac structure, systolic function, electrical activities and concentration of B - type natriuretic peptide precursor in patients with Chronic Heart Failure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Harbin Medical University
• Treatments: Lidocaine; Ropivacaine

Criteria

Inclusion Criteria:

• 20-70 years old

• more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

• NYHA functional class III-IV, ejection fraction ≤45%

• NT-proBNP>400ng/L

Exclusion Criteria:

• first episode of acute heart failure

• unrepaired valvular heart disease accompanied with Hemodynamic changes

• hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension

• Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy

• right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease

• overt renal decompensation: serum creatinine>2.1mg/dl(186umol/L)

• severe hepatic dysfunction, transaminase or alkaline phosphatase > 3 times the upper limit of normal

• Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc)

• life expectancy shorter than 6 months

• patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination

• Spine Deformity or skin infection at puncture site

• participate in any clinical drug trials in the three months

• the patients who do not sign the informed consent, unable or unwilling to comply with the requirements of the protocol or unsuitable for the study